Pharmaceuticals and vector-control programmes have greatly diminished the once-widespread disease, but sustained effort will ...

Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...

Azafaros B.V. today announced that its lead asset, nizubaglustat, has been granted orphan drug designation from regulatory ...

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

After nearly a decade of machine learning innovations, the FDA has issued its first draft guidance on the use of AI in drug ...

Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to ...

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the ...

Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, ...

Everest Medicines announces the implementation of Nefecon NRDL pricing in China for the treatment for IgA nephropathy: Shanghai, China Saturday, January 4, 2025, 10:00 Hrs [IST] E ...